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ABSTRACT

With the rapid increase in the frequency of azole-resistant species, combination therapy appears
to be a promising tool to augment the antifungal activity of azole drugs against resistant Candida
species. Here, we report the effect of aprepitant, an antiemetic agent, on the antifungal activities
of azole drugs against the multidrug-resistant Candida auris. Aprepitant reduced the minimum
inhibitory concentration (MIC) of itraconazole in vitro, by up to eight-folds. Additionally, the
aprepitant/itraconazole combination interfered significantly with the biofilm-forming ability of
C. auris by 95 ± 0.13%, and significantly disrupted mature biofilms by 52 ± 0.83%, relative to the
untreated control. In a Caenorhabditis elegans infection model, the aprepitant/itraconazole combination significantly prolonged the survival of infected nematodes by ~90% (five days postinfection) and reduced the fungal burden by ~92% relative to the untreated control. Further, this
novel drug combination displayed broad-spectrum synergistic interactions against other medically important Candida species such as C. albicans, C. krusei, C. tropicalis, and C. parapsilosis (ƩFICI
ranged from 0.08 to 0.31). Comparative transcriptomic profiling and mechanistic studies indicated
aprepitant/itraconazole interferes significantly with metal ion homeostasis and compromises the
ROS detoxification ability of C. auris. This study presents aprepitant as a novel, potent, and broadspectrum azole chemosensitizing agent that warrants further investigation.

Introduction
Candida auris is an emerging fungal pathogen that has
been recently implicated in numerous global outbreaks of
life-threatening candidemia, leading to significant morbidity and high rates of mortality [1,2]. Recently, the U.S.
Centers for Disease Control and Prevention (CDC) has
classified C. auris as an urgent threat that requires
immediate intervention [3]. Unfortunately, resistance to
major antifungal agents, including to the first-line therapeutics, was reported to be common among C. auris isolates [4]. According to the CDC, 90% of C. auris isolates
are resistant to the antifungal activity of fluconazole and
around 30% of isolates are resistant to amphotericin B [5].
The unique multidrug resistance nature of C. auris combined with its ability to be efficiently transmitted among
patients are key challenges that hinder the development of
effective control and containment of C. auris [1,6–8].
Currently, only three classes of systemic antifungal
drugs (azoles, polyenes, and echinocandins) are available for the treatment of invasive Candida infections
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[9]. Azole drugs target ergosterol biosynthesis through
the inhibition of lanosterol 14 alpha methyltransferase
(Erg11p) resulting in depletion of the vital cell membrane component, ergosterol, and accumulation of
cytotoxic metabolites [10]. Owing to safety, the spectrum of activity, and pharmacokinetic considerations
such as oral bioavailability, azole antifungal drugs
have gained preference as vital therapeutics to control
various types of mycotic infections [11–14]. However,
the extensive dependence on azole drugs has contributed to the increased rate of azole-resistance among
fungal species [15,16]. Overexpression or mutation of
ERG11, in addition to the upregulation of ABC and
MFS efflux transporters, are known to be major triggers
of azole resistance in Candida species [17].
Considering the limited therapeutic options and the
increased rate of drug resistance in C. auris, there is
a pressing need for novel antifungal agents and codrugs capable of restoring or enhancing the antifungal
activity of azole drugs. Historically, drug combinations
have been utilized efficiently to treat various bacterial
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and viral infections and to fight cancer [18–21].
However, this approach has not been fully exploited
in medical mycology despite the immediate need to
discover new treatment strategies, especially with the
current dearth in available therapeutics and the
increased frequency of multidrug-resistant isolates.
In a whole-cell screening study aimed at identifying
novel azole chemosensitizing agents (unpublished
data), we noticed that the antiemetic agent aprepitant
was able to restore the antifungal activity of fluconazole
against the test C. auris isolate. Here, we investigated
the interactions between aprepitant and different azole
drugs against multiple C. auris isolates and other clinically important Candida species. Additionally, comparative transcriptomic profiling and mechanistic
studies were performed to identify the potential
mechanism by which aprepitant enhances the antifungal activities of azole drugs.

Materials and methods
Fungal strains, reagents, and chemicals
Sources and descriptions of the fungal strains used in
this study are provided in Supplementary Table S1.
Yeast-peptone dextrose (YPD) agar and broth were
purchased from Becton, and Dickinson Company
(Franklin Lakes, NJ). 3-(N-Morpholino) propanesulfonic acid (MOPS) was purchased from Sigma-Aldrich
(St. Louis, MO). RPMI 1640 powder, supplemented
with glutamine and lacking NaHCO3, was obtained
from Thermo Fisher Scientific (Waltham, MA). Johns
Hopkins Clinical Compounds Library (JHCCL) was
obtained from the school of medicine at Johns
Hopkins University and was used to identify the azole
chemosensitizing activity of aprepitant. The library was
screened at 16 µM against C. auris AR0390 in the
presence or absence of a subinhibitory concentration
of fluconazole (32 µg/ml). Fluconazole was purchased
from Fisher Scientific (Pittsburgh, PA). Itraconazole,
voriconazole, and aprepitant were purchased from
TCI America (Portland, OR). Gentamicin sulfate was
obtained from Chem-Impex International Inc. (Wood
Dale, IL).
Microdilution checkerboard assays
Aprepitant and azole drugs (fluconazole, voriconazole,
and itraconazole) were tested alone and in combinations against different Candida species using standard
broth microdilution checkerboard assays, as previously
described [22–24]. The ΣFICI (fractional inhibitory
concentration index) was used to evaluate the

®

VIRULENCE

1467

interactions between the tested drugs. Interactions
were deemed to be synergistic (SYN) when ΣFICI
values were ≤0.50, additive (ADD) when ΣFICI values
were >0.50 and ≤1, and indifferent (IND) when ΣFICI
values were >1 and ≤4 [25].

Time-kill assay
To study the effect of aprepitant/itraconazole on the
growth kinetics of C. auris, a time-kill assay was conducted, as previously described [26–29]. Briefly, exponential-phase C. auris AR0390 cells were diluted with
RPMI 1640 medium to ~1 × 105 CFU/ml. Cells were
incubated with aprepitant (10 µg/ml), itraconazole
(1 µg/ml), or a combination of both agents for 24 h at
35°C. Following incubation, the number of viable cells
was determined at specific time points (0, 6, 12, and
24 h). The time-kill curve was constructed by plotting
viable colony forming units against time. The results
are presented as the average values of triplicate
measurements.

Effect of aprepitant/itraconazole combination
against premature and mature C. auris biofilms
To assess the antibiofilm activity of aprepitant/itraconazole against C. auris, overnight cultures of C. auris
AR0390 (~1 × 105 CFU/ml) in RPMI 1640 were transferred onto tissue culture-treated 96-well plates and
incubated for 2 h at 35°C to allow cell adhesion. Then
aprepitant (10 µg/ml), itraconazole (1 µg/ml), or a combination of both agents were added, and the plates were
incubated for 24 h at 35°C. Cells treated with DMSO
(1%), the drugs’ solvent, served as a negative control.
Following incubation, RPMI 1640 medium was discarded and the formed biofilms were carefully washed
twice with PBS before being quantified, using the XTT
reduction assay [26,30].
To assess the activity of aprepitant/itraconazole
against mature biofilms, C. auris cells (at ~1 × 105
CFU/ml) were seeded in tissue culture-treated 96-well
plates and incubated for 24 h at 35°C to allow for the
formation of mature biofilms [31–33]. Fresh RPMI
1640 media supplemented with aprepitant, itraconazole, or aprepitant/itraconazole, at the same concentrations indicated above, were added to the formed
biofilms and incubated for another 24 h at 35°C.
After incubation, biofilms were carefully washed and
quantified by the XTT reduction method. All treatments were conducted in triplicates and data represent
the average ± SD.
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Effect of aprepitant/itraconazole against other
Candida species
To investigate the effect of aprepitant on the antifungal
activity of itraconazole against other medically important Candida species, checkerboard assays were utilized
and ΣFIC indices were calculated as mentioned above.
The aprepitant/itraconazole combination was assessed
against C. albicans (n = 4), C. glabrata (n = 3), C. krusei
(n = 3), C. tropicalis (n = 2), and C. parapsilosis (n = 2).
Additionally, 5 µl samples from representative Candida
cultures that displayed enhanced susceptibility to the
aprepitant/itraconazole combination were spotted onto
YPD agar plates and incubated for 24 h at 35°C before
scanning the plates and determination of CFU counts.
RNA extraction
Exponential-phase cultures of C. auris AR0390 were
treated (in duplicates) with DMSO (1%), aprepitant
(10 µg/ml), itraconazole (1 µg/ml), or a combination
of both drugs. All treated cultures were incubated for
3 h at 30°C. The cells were pelleted, washed twice with
PBS, and RNA was isolated using an Ambion Ribopure
yeast kit. The RNA quality was checked on
a bioanalyzer Nano chip (Agilent) and all RNAs used
for downstream experiments were determined to have
RNA integrity numbers (RIN) of 9.5 and above. The
SuperScript III First-Strand kit (Invitrogen) was used to
prepare cDNA, following the manufacturer’s
guidelines.
RNA sequencing and enrichment analysis of
differentially expressed genes (DEGs)
Paired-end, 2 × 150 bp reads were sequenced on
a NovaSeq6000. Reads were quality trimmed and
Illumina TruSeq adapter sequences were removed
using fastp [34]. HISAT2 (v2.1) was used to align
reads to the Candida auris NCBI reference genome
version B11221 [35]. FeatureCounts (v2.1) was used
to count the read numbers mapped of each gene [36].
FPKM values of each gene were calculated based on the
length of the gene in the associated annotation GTF file
as well as reads count mapped to each gene. Differential
expression analysis was performed on raw count data
using the edgeR Bioconductor package (v3.16.5)
[37,38]. The P values were adjusted using the
Benjamini & Hochberg method [39]. A corrected
P-value of 0.005 and an absolute foldchange of two
was set as the threshold for significant differential
expression. Differentially expressed genes were annotated by blasting the sequences of identified DEGs

against the Candida Genome Database (CGD) and by
using blasts against C. albicans SC5314 (taxid:237561)
with an e-value cutoff of 0.01 [40]. Gene Ontology
(GO) enrichment analysis of differentially expressed
genes was implemented by the ClusterProfiler
Bioconductor package (v2.4.3) [41]. GO terms with
corrected P-values < 0.05 were considered significantly
enriched within the differentially expressed genes lists.

Real-time quantitative reverse transcription
(RT-qPCR)
To validate the RNA-Seq results, we conducted quantitative real-time (RT) PCR assays to quantify the expression of six genes (ERG1, ERG2, ERG10, FRT1, ZRT2,
and CTR1). Gene expression levels were calculated
using the 2−ΔΔCT method [42]. Gene expression was
internally normalized to ACT1 and compared to the
untreated control (DMSO 1%). All primers used in this
study were provided in Supplementary Table S2.

Effect on ROS levels in C. auris cells
The Image-iT™LIVE Green Reactive Oxygen Species
(ROS) detection kit (Molecular Probes, Inc., Eugene,
OR) was utilized to measure ROS levels, as previously
described [27]. Briefly, exponential-phase C. auris
AR0390 was adjusted to ~ 1 × 106 CFU/ml in PBS in
the presence or absence of FeSO4 (50 µM). Cells were
treated with either aprepitant (10 µg/ml), itraconazole
(1 µg/ml), or a combination of both drugs, while
DMSO (1%) treated culture was used as a negative
control. All treatments were continued for 3 h at 35°
C, then cells were pelleted, washed twice with PBS, and
5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA) dye, at a final concentration of 50 µM, was added. Cells were then incubated
for 1 h at 35°C. After incubation, cells were washed
twice with PBS and the fluorescence intensity was measured spectrophotometrically at 495/529 nm. Data
represent the average of three measurements ±SD.

Effect of iron supplementation on the antifungal
activity of aprepitant/itraconazole
To investigate the effect of iron supplementation on
the synergistic relationship between aprepitant and
itraconazole against C. auris, a time-kill assay was
performed as described above, and RPMI 1640 with/
without ferrous sulfate (50 µM) was used as the assay
medium. Cultures were incubated at 35°C for 24 h
and then 5 µl samples of each treatment were spotted
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onto YPD agar plates and incubated at 35°C for
another 24 h before scanning the plates.

Caenorhabditis elegans infection model
To assess the in vivo efficacy of the aprepitant/itraconazole combination, a C. elegans infection model was
utilized as previously discribed [9,11,26]. Briefly, synchronized worms [strain AU37 genotype glp-4(bn2) I;
sek-1(km4) X] at L4 phase were incubated in 5 ml of
YPD broth containing C. auris AR0390 (adjusted at
~1 × 106 CFU/ml) for 3 h at room temperature.
Following infection, worms were washed five times
with PBS to remove non-ingested cells and then suspended in M9 buffer containing 20% RPMI 1640.
Infected worms were distributed into groups (~20
worms/group) and then treated (in triplicates) with
either DMSO (1%), aprepitant (10 µg/ml), itraconazole
(1 µg/ml), or a combination of both drugs. Worms
were then incubated with test agents at 25°C for 24 h
before being washed twice with PBS and beaten vigorously with silicon carbide beads, for at least 2 min, to
release C. auris cells. C. elegans lysates were serially
diluted and plated over YPD agar plates containing
gentamicin (100 µg/ml). Plates were incubated for
24 h at 35°C before viable CFU per worm was
determined.
In another experiment, worms were incubated in
5 ml of YPD broth containing C. auris AR0390
(adjusted at ~1 × 106 CFU/ml) for 3 h at room temperature. Infected worms were treated with DMSO
(1%), aprepitant (10 µg/ml), itraconazole (1 µg/ml), or
a combination of both drugs. The survival of C. elegans
was monitored and recorded for five days. Data are
presented as percent survival of infected C. elegans
using a Kaplan-Meier survival curve generated using
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
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Statistical analyses
Statistical analysis was performed using GraphPad
Prism 6.0 (Graph Pad Software, La Jolla, CA, USA).
One-way ANOVA and Dunnett’s test for multiple comparisons were used to assess the statistical significance
(P < 0.05) between treated and untreated groups.
Kaplan-Meier survival curves were assessed by the logrank test for statistical significance.

Results
Azole chemosensitizing activity of aprepitant
against C. auris isolates
To identify novel adjuvants to overcome azole resistance in C. auris, we explored the azole chemosensitizing activity of ~1600 FDA-approved drugs in the Johns
Hopkins Chemical Library (unpublished data). Our
initial screen identified aprepitant (an antiemetic
agent) as a potent hit compound that restored the
antifungal activity of fluconazole against the multidrugresistant strain C. albicans AR0390. This observation
encouraged us to explore the interactions between
aprepitant and commonly used azole drugs in vitro
against a panel of ten C. auris isolates obtained from
the Antimicrobial Resistance Isolate Bank (CDC). To
assess these interactions, we used standard microdilution checkerboard assays and calculated the fractional
inhibitory concentration indices (ƩFICI). As shown in
Table 1, aprepitant was able to enhance the antifungal
activity of fluconazole against seven isolates with
a synergistic relationship observed against four isolates
(ƩFICI ranged from 0.09 to 0.50) and an additive relationship observed against three isolates (ƩFICI ranged
from 0.51 to 0.63). Based on the current tentative
breakpoints for azole resistance, aprepitant was able to
restore the fluconazole susceptibility only in two fluconazole-resistant isolates, AR0388, and AR0390. When

Table 1. Effect of aprepitant on the antifungal activity of fluconazole (FLC), voriconazole (VRC), and itraconazole (ITC) against C. auris
clinical isolates.
MIC (µg/ml)
C. auris
Isolates
AR0381
AR0382
AR0383
AR0384
AR0385
AR0386
AR0387
AR0388
AR0389
AR0390

APR
> 128

FLC
1
1
256
128
256
256
1
256
256
256

VRC
0.0078
0.0625
0.5
0.5
4
2
0.0312
0.5
2
0.5

Combination with FLC
ITC
0.25
0.25
0.5
0.25
0.5
0.5
0.125
1
1
1

APR/FLC
(µg/ml)
0.5/0.5
1/0.5
2/256
2/64
2/256
16/128
0.5/0.5
8/8
8/256
8/8

ƩFIC
0.50
0.51
1.02
0.52
1.02
0.63
0.50
0.09
1.06
0.09

Mode
SYN
ADD
IND
ADD
IND
ADD
SYN
SYN
IND
SYN

Combination with VRC
APR/VRC
(µg/ml)
8/0.007
8/0.031
8/0.25
8/0.25
4/2
4/1
4/0.015
8/0.062
8/2
8/0.062

ƩFIC
1.06
0.56
0.56
0.56
0.53
0.53
0.53
0.19
1.06
0.19

Mode
IND
ADD
ADD
ADD
ADD
ADD
ADD
SYN
IND
SYN

Combination with ITC
APR/ITC
(µg/ml)
2/0.125
8/0.0312
8/0.125
8/0.0312
8/0.125
8/0.125
8/0.0312
2/0.125
2/0.5
4/0.125

ƩFIC
0.52
0.19
0.31
0.19
0.31
0.31
0.31
0.14
0.52
0.16

Mode
ADD
SYN
SYN
SYN
SYN
SYN
SYN
SYN
ADD
SYN

*ΣFICI (fractional inhibitory concentration index) was used to measure the interaction between the tested combinations. ΣFICI interpretation corresponded to
the following definitions: synergism (SYN), ΣFICI ≤0.5; additivity (ADD), ΣFICI >0.5 and ≤1; and indifference (IND), ΣFICI >1 and ≤4.
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tested in combination with voriconazole, aprepitant
was able to enhance the antifungal activity of voriconazole against eight isolates, with a synergistic relationship observed against two isolates (ƩFICI = 0.19) and
an additive relationship observed against six isolates
(ƩFICI ranged from 0.53 to 0.56). However, aprepitant
failed to re-sensitize any of the tested voriconazoleresistant isolates (n = 3) that exhibited MIC ≥1 µg/ml.
Interestingly, when combined with itraconazole, aprepitant was able to enhance the antifungal activity of
itraconazole against all ten tested isolates, resulting in
a synergistic relationship observed against eight isolates
(ƩFICI ranged from 0.14 to 0.31) and an additive relationship observed against two isolates (ƩFICI = 0.52).
Importantly, aprepitant was able to re-sensitize all
tested isolates (n = 3) that displayed reduced susceptibility to itraconazole (MIC ≥1 µg/ml). Since aprepitant
interacted more favorably with itraconazole against
C. auris, the combination between aprepitant and itraconazole was selected for further investigation.

same concentrations each drug was tested alone) displayed fungicidal activity against the test isolate generating ~ 3-log10 reduction in the CFU count over
24 hours.
Effect of aprepitant/itraconazole against C. auris
biofilms
As shown above, the aprepitant/itraconazole combination exerted fungicidal activity against planktonic
C. auris. To investigate whether a similar effect could
be observed against C. auris biofilms, we utilized the
XTT reduction assay to examine the effect of aprepitant/itraconazole against early-stage and mature biofilms. As shown in Figure 2(a), the combination of
aprepitant (at 10 µg/ml) and itraconazole (at 1 µg/ml)
significantly inhibited the biofilm-forming ability of the
test isolate by ~95 ± 0.13% compared to the untreated
control. However, single treatments with either

a
Aprepitant/itraconazole exerts a fungicidal effect
against C. auris AR0390
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To investigate the killing kinetics of the aprepitant/
itraconazole combination against C. auris, a time-kill
assay was conducted. As shown in Figure 1, aprepitant
(at 10 µg/ml), by itself, did not produce any observable
antifungal activity against the test isolate (AR0390).
Itraconazole, at 1 × MIC (1 µg/ml), exhibited fungistatic activity for 12 h post-incubation; however, rapid
fungal re-growth was observed thereafter. Interestingly,
the combination of aprepitant and itraconazole (at the
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Figure 1. Time-kill assay of aprepitant (APR) at 10 µg/ml, itraconazole (ITC) at 1 µg/ml, or a combination of both agents at
the same concentration as tested alone. Test agents were
evaluated against C. auris AR0390 over a 48-hour incubation
period at 35 °C. Cells treated with DMSO (1%) served as
a negative untreated control. Error bars represent standard
deviation values.

Figure 2. The anti-biofilm activity of aprepitant (APR)/itraconazole (ITC) against C. auris. (a) The inhibitory effect of the
aprepitant (10 µg/mL)/itraconazole (1 µg/mL) combination on
the formation of C. auris AR0390 biofilms as determined by the
XTT reduction assay. (b) The ability of the aprepitant/itraconazole combination to diminish the metabolic activity of mature
C. auris AR0390 biofilms. Data are shown as means ± SD. *
indicates a statistical significance (P < 0.05) relative to the
untreated control (P < 0.05), whereas #, indicates a statistical
significance (P < 0.05) relative to the treatment with either
aprepitant or itraconazole alone. Statistical significance was
assessed by one-way ANOVA using Dunnett’s test for multiple
comparisons.
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ranged from 0.08 to 0.31) against all isolates, except
for C. glabrata isolates where an indifferent effect was
observed (ƩFICI = 1.02). These synergistic interactions
were further demonstrated using spot assays. As shown
in Figure 3(b), the aprepitant/itraconazole combination
inhibited the visual growth of C. albicans (TWO7243),
C. krusei (ATCC 14243), C. tropicalis (ATCC 1369),
and C. parapsilosis (ATCC 22019), and reduced the
CFU counts by ~ 2–4 orders of magnitude relative to
the untreated control, as shown in Figure 3(c).

aprepitant or itraconazole at the respective concentrations failed to interfere with the biofilm-forming ability
of the test isolate.
When tested against mature C. auris biofilms, the
aprepitant/itraconazole combination, at the same concentrations, was able to significantly reduce the viability
of C. auris AR0390 cells present in mature biofilms by
52 ± 0.83% (Figure 2(b)). As expected, neither aprepitant nor itraconazole alone, at the respective concentrations, was able to interfere with the viability of C. auris
cells within mature biofilms. These data indicate the
potent ability of aprepitant/itraconazole to interfere
with both the early and late phases of C. auris biofilms.

Transcriptomic profiling of C. auris treated with
aprepitant/itraconazole
To gain insight into the molecular mechanism(s) by
which aprepitant interacts synergistically with azole
drugs, we performed comparative transcriptomic analysis of C. auris AR0390 treated with DMSO (1%),
aprepitant (10 µg/ml), itraconazole (1 µg/ml), or a combination of both drugs. A total of 81.9 million reads
were obtained with over 95% mapping rates observed
across all samples. The sequence reads of all samples
were deposited in the NCBI sequence read archive
(GEO) under the accession number of (GSE148749).
The Bioconductor package edgeR was used to identify
differentially expressed genes (DEGs) between groups.
Genes with an adjusted P-value <0.05 and that showed
greater than a two-fold (up or down) change in expression were considered differentially expressed. As shown
in Figure 4(a), a total of 34 DEGs (19 upregulated + 15

Effect of aprepitant/itraconazole against other
Candida species
The potent synergistic interaction observed between
aprepitant and itraconazole against all C. auris isolates
tested encouraged us to examine whether the aprepitant/itraconazole combination would exert a similar
effect against other clinically important Candida species. Using standard microdilution checkerboard
assays, we examined the interactions between aprepitant and itraconazole against a panel of 14 Candida
species including C. albicans (n = 4), C. glabrata
(n = 3), C. krusei (n = 3), C. tropicalis (n = 2), and
C. parapsilosis (n = 2). As shown in Figure 3(a) and
Supplementary Table S3, aprepitant exerted
a synergistic relationship with itraconazole (ƩFICI
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Figure 3. Interaction between aprepitant and itraconazole against different Candida species. (a) ƩFICI (fractional inhibitory
concentration index) values were calculated from checkerboard assays. Cultures of C. albicans TWO7243, C. krusei ATCC 14243,
C. tropicalis ATCC 1369, and C. parapsilosis ATCC 22019 were treated with APR (10 µg/ml) and ITC (0.25 × MIC), either alone or in
combination. Treated cultures were incubated at 35°C for 24 h before being spotted onto YPD agar plates and reincubated for an
additional 24 h. Plates were then scanned (b) and CFU count was performed (c).
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downregulated) were identified in the aprepitant/itraconazole treated sample (Figure 4(a) and Table 2).
Genes involved in ergosterol synthesis (ERG1, ERG2,
ERG10, ERG24), stress responses (DDR48 and RTA3),
and drug transporters (CDR1, MDR1, DUR3) were

upregulated in the aprepitant/itraconazole treated sample. Additionally, the iron-regulated 1,3-beta glucanlinked cell wall gene (PIR1) and the vacuolar calcium
P-type ATPase (PMC1) were also among the upregulated DEGs. On the other hand, the aprepitant/
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Figure 4. Transcriptional comparison of C. auris AR0390 treated with aprepitant (APR), itraconazole (ITC), or a combination of both
versus the untreated control. (a) Heat map of FPKM values of DEGs of each treatment versus the untreated control, scaled by row. (b)
Volcano blot of DEGs from C. auris AR0390 treated with aprepitant/itraconazole (APR/ITC) at 10/1 µg/ml. (c) Volcano blot of DEGs
from C. auris AR0390 treated with aprepitant (APR) at 10 µg/ml. (d) Volcano blot of DEGs from C. auris AR0390 treated with
itraconazole (ITC) at 1 µg/ml. Significant down-regulated DEGs are shown in green, whereas significant up-regulated DEGs are shown
in red.
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Table 2. List of differentially expressed genes (DEGs) for C. auris AR0390 treated with a combination of aprepitant (10 µg/ml) and
itraconazole (1 µg/ml).
ID
40027169
40027170
40029385
40027445
40029696
40028877
40027663
40026070
40029380
40028922
40029539
40026699
40026939
40029413
40027889
40025324
40027146
40030172
40029187
40026984
40025409
40030782
40025820
40029256
40029691
40025314
40029715
40025414
40027963
40028953
40028243
40027842
40029690
40030199

Name

Log2 Fold Change

HGT6
HGT8
LIP2
FTR1
ZRT2
CTR1
orf19.6983
TYE7
CDG1
ADH1
PDC11
HGT12
JEN2
YHB1
PMC1
DUR3
ERG2
MDR1
orf19.3988
ERG1
ERG10
PIR1
CDR1
orf19.5169
INO1
CAN1
ERG24
RCT1
RTA3
DDR48

−4.90
−3.29
−3.09
−2.63
−2.61
−2.48
−2.24
−2.21
−2.20
−2.04
−2.03
−1.87
−1.82
−1.79
−1.78
1.78
1.82
1.88
1.97
1.98
1.99
2.04
2.04
2.22
2.23
2.25
2.29
2.34
2.38
2.53
2.60
2.72
3.02
3.19

P-value
3.1
5.5
1.5
1.5
1.2
9.1
7.2
8.5
1.7
5.2
5.2
1.9
3.2
4.1
4.1
2.3
1.8
9.2
3.7
5.8
2.8
5.9
2.3
2.3
2.7
1.5
9.7
6.6
7.9
1.2
2.2
4.8
1.4
1.1

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

10−20
10−10
10−6
10−6
10−3
10−6
10−5
10−5
10−4
10−4
10−4
10−3
10−3
10−3
10−3
10−5
10−5
10−6
10−6
10−6
10−6
10−6
10−6
10−7
10−7
10−7
10−7
10−8
10−8
10−8
10−9
10−10
10−11
10−12

CGD* Description
Putative high-affinity major facilitator superfamily (MFS) glucose transporter
High-affinity glucose transporter of the major facilitator superfamily
Secreted lipase, expressed in the alimentary tract, but not during oral infection
High-affinity iron permease, required for mouse virulence
Protein of unknown function
Zinc transporter, essential for zinc uptake
Ortholog(s) have copper/iron transmembrane transporter activity
Protein of unknown function, repressed by nitric oxide
Transcription factor, control of glycolysis, required for biofilm formation
Putative cysteine dioxygenases, role in conversion of cysteine to sulfite
Alcohol dehydrogenase
Pyruvate decarboxylase, antigenic fluconazole, farnesol induced
Glucose, fructose, mannose transporter, major facilitator superfamily
Dicarboxylic acid transporter, regulated by glucose repression
Nitric oxide dioxygenase, acts in nitric oxide scavenging/detoxification
Vacuolar calcium P-type ATPase, mutants show increased resistance to fluconazole
High-affinity spermidine transporter
C-8 sterol isomerase, an enzyme important for ergosterol biosynthesis
Plasma membrane MDR/MFS multidrug efflux pump
Putative adhesin-like protein
Squalene epoxidase, ergosterol biosynthesis
Acetyl-CoA acetyltransferase, role in ergosterol biosynthesis
Protein of unknown function
1,3-beta-glucan-linked cell wall protein, iron regulated
Protein of unknown function
Multidrug transporter of ABC superfamily
Has domain(s) with predicted amidase activity
Protein of unknown function
nositol-1-phosphate synthase/glycosylation predicted
Basic amino acid permease
C-14 sterol reductase has a role in ergosterol biosynthesis
Fluconazole-induced protein, required for caspofungin tolerance
Putative lipid translocase influences the susceptibility of C. albicans to fluconazole
Immunogenic stress-associated protein

*Descriptions of the identified DEGs obtained from the Candida Genome Database (CGD) combined with a tBLASTx search.

itraconazole combination resulted in the downregulation of genes responsible for metal ion transport such
as FTR1 (iron transporter), ZTR2 (zinc transporter),
and CTR1, which is important for both iron and copper
transport. Also, several high-affinity glucose transporters (HGT6, HGT8, HGT12) were among the downregulated DEGs in the aprepitant/itraconazole treated
sample.
With regards to single treatments with either aprepitant or itraconazole, no significant change in C. auris’
transcriptome was observed in the aprepitant treated
condition (Figure 4(c)). However, a total of 18 DEGs
(10 upregulated + 8 downregulated) were detected in
samples treated with itraconazole alone (Figure 4(d)
and Table 3). Among the upregulated genes in the
itraconazole treated condition were amino acid permeases (DIP5 and CAN1), stress-associated genes
(DDR48 and PGA31), ergosterol biosynthesis (ERG24),
and a redox related gene, ferric reductase (FRE3).
In order to obtain an overall insight into the impact of
aprepitant/itraconazole on the C. auris transcriptome, we
performed a Gene Ontology (GO) analysis of the identified DEGs. Twenty-six GO terms were significantly overrepresented (enriched) in the aprepitant/itraconazole
treated
condition.
However,
no
significant

overrepresented GO terms were found in the itraconazole treated condition. Among the enriched GO terms,
only one GO term related to membrane components was
upregulated in the aprepitant/itraconazole sample
(Figure 5(a) and Supplementary Table S4). However,
a total of 25 GO terms were found to be downregulated
in the aprepitant/itraconazole treated sample (Figure 5(b)
and Supplementary Table S5). Notably, 18 downregulated GO terms were found to be associated with membrane transport processes, of which 11 GO terms were
involved in metal ions and cation transport, indicating
the negative impact that aprepitant/itraconazole combination has on the ions homeostasis in C. auris. Of note,
since all genes that demonstrated differential expression
in response to aprepitant/itraconazole treatments have
orthologs in other Candida species, we expect this combination would have a similar mechanism of action in all
susceptible species.
Validation of RNA-Seq data
Based on the RNA-Seq data, we selected six DEGs (three
downregulated and three upregulated) exhibiting a broad
range of differential expression for validation by RTqPCR. Of note, three genes selected for analysis are
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Table 3. List of differentially expressed genes (DEGs) for C. auris AR0390 treated with itraconazole (1 µg/ml).
ID

Name

Log2 Fold Change

P-value

CGD* Description

40027169
40027170
40029385
40029539
40027889
40029413
40028527
40030546
40025268
40026925
40028209
40027842
40029187
40030199
40030120
40028243
40025718
40028953

HGT6
HGT8
LIP2
ADH1
YHB1
JEN2
TDH3
DAL81
PGA30
DIP5
PRA1
RCT1
MDR1
DDR48
PGA31
ERG24
FRE3
CAN1

−2.9273
−2.7557
−2.3233
−2.3056
−2.245
−2.1117
−2.0678
−2.0262
1.9233
1.9692
2.0941
2.1026
2.1045
2.1539
2.3457
2.3585
2.7106
3.4505

9.6 x 10−8
6.1 x 10−7
4.5 x 10−4
7.7 x 10−5
1.2 x 10−4
4.4 x 10−4
4.8 x 10−4
3.7 x 10−4
3.1 x 10−4
4.7 x 10−4
4.5 x 10−4
4.5 x 10−4
4.4 x 10−4
3.7 x 10−4
7.7 x 10−5
5.2 x 10−5
1.09 x 10−6
3.5 x 10−10

Putative MFS glucose transporter
High-affinity glucose transporter of the major facilitator superfamily
Secreted lipase
Alcohol dehydrogenase
Nitric oxide dioxygenase
Dicarboxylic acid transporter
NAD-linked glyceraldehyde-3-phosphate dehydrogenase
RNA polymerase II repressing transcription factor binding activity
Predicted GPI-anchored protein
Dicarboxylic amino acid permease
Cell surface protein that sequesters zinc from host tissue
Fluconazole-induced protein, required for caspofungin tolerance
Plasma membrane MDR/MFS multidrug efflux pump
Stress-associated protein, induced by benomyl/caspofungin/ketoconazole
Protein associated with cellular response to chemical stimulus
C-14 sterol reductase has a role in ergosterol biosynthesis
Protein with similarity to ferric reductase Fre10p
Basic amino acid permease

* Descriptions of the identified DEGs obtained from the Candida Genome Database (CGD) combined with a tBLASTx search.

involved in ergosterol biosynthesis and three genes are
involved in metal ion homeostasis. Consistent with the
RNA-Seq data, the qPCR analysis showed significant
differential expression of the tested genes and confirmed
the significant overexpression of ergosterol biosynthesisrelated genes (ERG1, ERG2, ERG10) and the significant
downregulation of metal transport-related genes (FTR1,
ZRT2, and CTR1) only in the cells treated with the
aprepitant/itraconazole combination (Figure 6).

Effect of aprepitant on ROS production
Since metal ion homeostasis is critical for multiple
biological processes, including redox regulatory
mechanisms, we were curious to examine the effect
of the aprepitant/itraconazole combination on the
ability of C. auris to detoxify reactive oxygen species
(ROS). As presented in Figure 7, aprepitant (at
10 µg/ml) significantly increased the intracellular
ROS levels by ~ 300% relative to the untreated control, while itraconazole treatment (at 1 µg/ml) significantly increased the ROS levels by 270% relative to
the untreated control. On the other hand, the aprepitant/itraconazole combination resulted in a more
prominent effect by increasing the ROS production
by ~ 600% relative to the untreated control.
Interestingly, when the assay medium was supplemented with iron, we noticed that C. auris cells
generated significantly lower levels of ROS as compared to iron-deficient media (Figure 7). This result
indicates that both aprepitant and the aprepitant/
itraconazole combination can interfere significantly

with ROS detoxification in C. auris, apparently
through the interference with metal ion transport.

Effect of metal ion supplementation on the
synergistic relationship between aprepitant and
itraconazole
Based on the data obtained from the transcriptomic analysis, several genes involved in metal ion transport were
found to be downregulated in cells treated with the aprepitant/itraconazole combination. Thus, it was rational to
investigate whether supplementation with exogenous
metal ions would reverse the synergistic interaction
observed between aprepitant and itraconazole. As shown
in Figure 8(a), iron supplementation interfered significantly with the synergistic relationship of aprepitant and
itraconazole, as demonstrated by a time-kill assay. Ferrous
sulfate (at 50 µM) completely negated the fungicidal activity of the aprepitant/itraconazole combination against the
test isolate (C. auris AR0390). This effect was further
demonstrated by a spotting assay where iron supplementation restored the visible growth of C. auris colonies on
YPD agar and eliminated the fungicidal effect of the
aprepitant/itraconazole combination (Figure 8(b)). It
should be noted that copper supplementation did not
affect the antifungal activity of aprepitant/itraconazole
(data not shown). Also, it was not possible to examine
the effect of zinc supplementation on the relationship
between aprepitant and itraconazole, as we noticed an
immediate precipitation reaction when zinc sulfate was
mixed with aprepitant. However, these results indicate
that interference with iron homeostasis is a key
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Figure 5. Enrichment analysis of all GO (gene ontology) terms of DEGs identified from the aprepitant/itraconazole
combination (APR/ITC) versus the untreated control. GO analysis of DEGs was implemented by the ClusterProfiler R package
and a P-value ≤ 0.05 was used as the cutoff parameter. Panel (a) displays up-regulated GO terms and panel (b) displays downregulated DEGs.

mechanism that contributes to the synergistic relationship
observed between aprepitant and itraconazole against
C. auris.
Efficacy of aprepitant/itraconazole in
a Caenorhabditis elegans model of C. auris
infection
To further corroborate the in vitro synergistic relationship observed between aprepitant and itraconazole, we

tested the in vivo efficacy of aprepitant/itraconazole
using C. elegans as an infection model. As shown in
Figure 9(a), treatment with aprepitant alone at 10 µg/ml
failed to reduce the fungal CFU burden in C. elegans
nematodes infected with C. auris AR0390. However,
itraconazole at 1 µg/ml (1 × MIC) was able to significantly reduce the fungal CFU burden by ~42 ± 3.6%,
compared to the untreated control. Interestingly, the
aprepitant/itraconazole combination was able to significantly reduce the C. auris CFU burden in the infected
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Figure 7. Effect of aprepitant/itraconazole on the ROS levels in the presence (+) or absence (-) of iron. Carboxy-H2DCFDA
probe was used to analyze ROS levels within C. auris AR0390 in the presence (+) or absence of iron source (FeSO4 50 µM). PBS
suspensions of C. auris cells, at 1× 106 CFU/ml, were treated with either aprepitant (APR, 10 µg/ml), itraconazole (ITC, 1 µg/ml), or
a combination of both for 3 h, and then were treated with H2DCFDA for 1 h, before measuring the fluorescence intensity as an
indication of ROS levels. Data are shown as means ± SD. An asterisk (*) indicates statistical significance (P < 0.05) between treated
and untreated groups (P < 0.05), whereas #, indicates statistical significance (P < 0.05) between treatment groups in the presence or
absence of iron. Statistical significance was assessed by one-way ANOVA using Dunnett’s test for multiple comparisons.

nematodes by ~92 ± 2.4%, compared to the untreated
control.
Next, we assessed the effect of aprepitant/itraconazole on the survival of infected nematodes. As shown in
Figure 9(b), only 20% of the untreated C. elegans nematodes survived C. auris infection for five days postinfection. As expected, aprepitant at 10 µg/ml did not
improve the survival of infected nematodes with respect
to the untreated control. However, itraconazole at 1 µg/
ml (1 × MIC) enhanced the survival of the infected
worms by ~ 40% (P < 0.05), compared to only 20% in
the untreated group. On the other hand, the aprepitant/
itraconazole combination significantly enhanced the
survival of the infected nematodes as ~ 90%

(P < 0.05) of C. elegans remained alive for five days.
Altogether, these findings indicate that aprepitant/itraconazole has a potent in vivo efficacy of treating
C. auris infection of C. elegans and warrants further
investigation in higher animal models.

Discussion
Drug repurposing is a valuable tool to identify novel
antimicrobial agents and co-drugs capable of enhancing
the activity of existing antimicrobials [27,43–46]. The
risk posed by the recently identified fungal pathogen
C. auris has prompted CDC to classify C. auris as an
urgent threat that requires immediate action [3].
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A hallmark trait of C. auris is its ability to resist multiple antifungal therapeutics, especially azoles. Here, we
utilized a whole-cell screening assay to evaluate the
azole chemosensitizing activity of ~1547 FDAapproved drugs and clinical molecules against the multidrug-resistant C. auris isolate AR0390. The screening
data (unpublished) revealed aprepitant, an NK1 antagonist used for the treatment of chemotherapy-associated
emesis, was able to restore the antifungal activity of
fluconazole against the test isolate. This observation
encouraged the exploration of the azole chemosensitizing activity of aprepitant against a panel of ten C. auris
isolates, in addition to several clinically important
Candida species. Checkerboard data indicate that aprepitant enhances the antifungal activity of azole drugs
against various Candida species. More specifically,
aprepitant interacted synergistically with itraconazole
against the majority of Candida isolates tested.
Additionally, combining aprepitant with itraconazole
changed the fungistatic nature of itraconazole and produced a prominent fungicidal effect against C. auris
AR0390 as demonstrated by the time-kill study. From
a clinical point of view, this observation is of interest
since fungicidal therapeutics are expected to improve
the clinical outcome of invasive Candida infections,
especially in patients with compromised immune systems [47,48].

A well-documented virulence factor of Candida
species is the notable ability to form adherent structures, known as biofilms, on surfaces of medical
devices [49–51]. Given the potent synergistic interaction and the fungicidal effect displayed by the aprepitant/itraconazole combination against planktonic
C. auris cells, it was of interest to examine whether
a similar effect could exist against the difficult-to-treat
fungal biofilms. While neither aprepitant nor itraconazole alone was able to interfere with the biofilmforming ability of C. auris, the aprepitant/itraconazole
combination was effective at reducing the metabolic
activity of fungal cells residing within premature and
mature biofilms. These observations may be of clinical
importance since biofilms are known to hinder the
penetration of antifungal drugs and host immune
effectors and also trigger the formation of Candida
persister cells, leading to poor clinical outcomes
[52,53].
To gain insight into the molecular mechanism by
which aprepitant interacts synergistically with azole
drugs against C. auris, we performed comparative transcriptomic profiling of C. auris cells treated with DMSO
(1%), aprepitant (10 µg/ml), itraconazole (1 µg/ml), or
the aprepitant/itraconazole combination (10/1 µg/ml).
Our data indicate that aprepitant, at the tested concentration, has no significant effect on C. auris’
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Figure 9. In vivo efficacy of aprepitant/itraconazole in Caenorhabditis elegans infected with C. auris. C. elegans nematodes
were infected with 1 × 107 CFU C. auris AR0390 and then treated with aprepitant (APR), at 10 µg/ml, and itraconazole (ITC), at 1 µg/
ml, either alone or in combination. Untreated worms served as a negative control. (a) C. auris AR0390 CFU burden/worm 24 h posttreatment. An asterisk (*) indicates statistical significance (P < 0.05) relative to the untreated control, while # indicates statistical
significance (P < 0.05) compared to the ITC treatment. Statistical significance was assessed by one-way ANOVA using Dunnett’s test
for multiple comparisons. (b) Kaplan-Meier survival curve, assessed by log-rank test for significance, of C. elegans nematodes infected
by C. auris AR0390 and treated with APR (10 µg/ml), ITC (1 µg/ml), or a combination of both agents.

transcriptome. However, a total of 18 and 34 genes
displayed significant changes in expression in groups
treated with itraconazole and aprepitant/itraconazole
respectively, compared to the untreated control. We
focused our attention on the differentially expressed
genes that were found to be specific to the aprepitant/
itraconazole treated group. We noticed that several
genes involved in metal ions transport were significantly
downregulated in cells treated with aprepitant/itraconazole, relative to the untreated control. This observation
suggests the aprepitant/itraconazole combination can
interfere with metal ion homeostasis in C. auris. Since
metal ions are key components of several essential genes,
it is expected that disturbances in metal ion homeostasis
would compromise multiple vital biological processes.
One striking example is the critical role of metal ions,
particularly iron, in the activity of many enzymes
involved in the detoxification of reactive oxygen species
(ROS) [54–56]. Thus, we sought to examine the effect of
aprepitant/itraconazole on the ROS detoxification ability
of C. auris. Interestingly, aprepitant by itself

compromised the ROS detoxification ability of C. auris,
resulting in elevated ROS levels (eight-times higher compared to the untreated control). This effect was even
more pronounced with the aprepitant/itraconazole combination which generated ~ 15-times more ROS levels,
compared to the untreated control. These increases in
ROS levels could explain the observed fungicidal activity
against planktonic and biofilms of C. auris as previously
demonstrated in other studies [57–59]. Further supporting the critical role of iron homeostasis in controlling
the intracellular ROS levels, we noticed that in iron
supplemented media, C. auris cells treated with aprepitant/itraconazole produced significantly lower ROS
levels, compared to iron-depleted media. Interestingly,
similar observations have been recorded in plant and
mammalian cells whereas high ROS levels were produced in iron depleting conditions [60,61], indicating
that iron homeostasis has a conservative protective role
against the ROS formation.
In Saccharomyces cerevisiae, iron homeostasis is
known to be an important regulator of ergosterol
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biosynthesis [62]. In iron depleting conditions, yeast cells
were reported to express higher mRNA levels of several
ERG genes such as ERG1, ERG7, and ERG11 [62].
Consistent with this phenomenon, we noticed that several genes involved in ergosterol biosynthesis were significantly upregulated such as ERG1, ERG2, and ERG10.
Our data also shows increased mRNA levels of ERG11,
however, this upregulation didn’t meet our strict criteria
for statistical significance. This upregulation of ERG
genes could be viewed as a compensatory mechanism
by which C. auris cells try to adapt to the reduced
ergosterol content. Indeed, previous studies have shown
that ergosterol depletion causes the upregulation of several genes involved in ergosterol biosynthesis [63,64].
Notably, iron homeostasis has been regarded as
a potential target for other azole chemosensitizing agents
such as doxycycline and lactoferrin [65,66]. Disturbance
in iron transport was reported to affect the membrane
permeability and enhance the activity of drugs that target
cell membrane biosynthetic pathways such as azoles [67].
Additionally, iron depletion is thought to suppress the
calcineurin pathway, leading to impairment of druginduced stress responses in Candida [68]. Thus, we
were interested to examine whether iron supplementation would weaken the synergistic interaction observed
between aprepitant and itraconazole against Candida.
Indeed, iron supplementation negated the fungicidal
activity of aprepitant/itraconazole as shown in our timekill kinetics. However, even in the presence of iron, the
aprepitant/itraconazole combination was still able to
exert a noticeable fungistatic activity against C. auris.
This suggests that other additional mechanisms may contribute to the synergistic relationship between aprepitant
and itraconazole. Of note, in contrast to iron, copper
supplementation did not interfere with the antifungal
activity of the aprepitant/itraconazole combination.
To conclude, our data indicate that aprepitant was
able to enhance the antifungal activity of azole drugs,
particularly itraconazole. The aprepitant/itraconazole
combination displayed broad-spectrum antifungal activity and was fungicidal against planktonic and biofilms of
C. auris, suggesting a promising clinical indication for the
treatment of azole-recalcitrant infections. Furthermore,
this novel drug combination demonstrated potent in vivo
efficacy in a C. elegans infection model. The synergistic
relationship between aprepitant and itraconazole appears
to be mediated through potent interference with metal
ion homeostasis, and the subsequent compromise in ROS
detoxifying mechanisms and ergosterol biosynthesis,
however, further molecular studies are needed to fully
understand the mechanism of the azole chemosensitizing
activity of aprepitant and its effect on the ergosterol
pathway. Moreover, efficacy in higher animal models
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and further clinical studies are needed to fully assess the
potential clinical use of aprepitant/itraconazole as a novel
drug combination with promising antifungal activity
against emergent multidrug-resistant C. auris.
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